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Abstract 
BACKGROUND:  Antithymocyte globulin (ATG) was found to decrease the morbidity of stem cell 
transplant (SCT) from matched unrelated donor (MUD) by decreasing the incidence of chronic graft vs 
host disease cGvHD, and at high doses, acute GvHD. We reviewed our results of MUD transplants where 
ATG was incorporated into the preparative regimen, and compared the results to patients prior to 
September 2006 where ATG was not used.  The primary endpoints were the effect on GvHD and lethal 
infectious complications.  
Method:  All stem cell transplants from MUD performed after 2000 at IU hospital for treatment of 
hematological malignancies using a myelo-ablative regimen were retrospectively reviewed.  
Result:  between 1/2000 and 3/2009 seventy nine  stem cell transplants were conducted using stem cells 
from MUD. 28 patients received ATG at a total dose of 7.5mg/kg vs 51 patients who did not receive 
ATG. Both groups were matched in term of age, sex, underline malignancies, degree of HLA-match, 
CMV serology, and conditioning regimens. Ninety-six percent of patient in ATG group received 
prophylaxis for GvHD using FK506/Sirolimus vs 14% in the no ATG group where a methotrexate based 
treatment was used (P<0.0001). The rate of Grade II-VI acute GVHD at day 100 was significantly lower 
in the ATG group compare to no ATG (14% vs 39%, P =0.011). Although however, the rate of chronic 
GVHD at 1 year was higher in ATG group than in the no ATG group, this was statistically not significant 
(43% and 23%; P=0.2). The rates of overall fungal infections and lethal fungal infections were 
comparable (14% and 10%) for ATG vs (17% and 11%) for no ATG (p =0.70). The rate of primary CMV 
infection (i.e., in patient not receiving corticosteroid treatment for GVHD) was higher in ATG group, 
although not statistically significant (31% vs 17%, P=0.27).  Day 100 mortality was 15% and 25% in 
ATG and no ATG group respectively, overall survival at 1 and 2 years was 47% and 31% for ATG group 
vs 49% and 36% for no ATG group (P>0.05),   Median time to death was 8.6 months (CI95%, 1.8-15.4) 
and 11.9 months (CI95%, 8-15.7) with P=0.7. The mortality from GVHD at 4 months was 0% in ATG 
group vs 12% in no ATG group (P =0.08).While the mortality rate from bacterial infection and sepsis 
were equivalent, more patients in the ATG group who did not receiving corticosteroid treatment for 
aGVHD died from viral and fungal infection (15% vs 0% at 8 months, P=0.013). 
Summary:  While ATG was associated with a trend toward lower mortality rate at day 100 due to 
statistically significant decrease in incidence and mortality of aGVHD, it was associated with increase 
rate of delayed-onset acute GVHD and statistically significant high rate of lethal viral and fungal 
infection leading to similar overall survival at 1 and 2 years. This study demonstrates the lack of overall 
benefit of ATG at dose of 7.5mg/kg. Further study to investigate the outcome of using lower doses of 
ATG to lower the rate of lethal infections while still reducing the risk of GvHD is recommended. 
